Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | terminated | Phase 1 / Phase 2 | 7 | Tango Therapeutics, Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT03127098 | QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer | terminated | Phase 1 / Phase 2 | 3 | NantCell, Inc.INDUSTRY | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00113256 | Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer | terminated | Phase 2 / Phase 3 | 39 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03136406 | QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | terminated | Phase 1 / Phase 2 | 3 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT02902484 | Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 14 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05116917 | Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.(INFLUENCE) | terminated | Phase 2 | 19 | Herlev HospitalOTHER | 1 | May 28, 2024 | clinicaltrials |
| NCT03450018 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX(SLC-0111-17-01) | terminated | Phase 1 / Phase 2 | 6 | British Columbia Cancer AgencyOTHER | 1 | May 24, 2024 | clinicaltrials |
| NCT03387098 | QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | terminated | Phase 1 / Phase 2 | 4 | ImmunityBio, Inc.INDUSTRY | 1 | May 22, 2024 | clinicaltrials |
| NCT04698915 | Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer | terminated | Phase 2 | 177 | Galera Therapeutics, Inc.INDUSTRY | 4 | May 21, 2024 | clinicaltrials |
| NCT04390243 | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation | terminated | Phase 2 | 6 | Academic and Community Cancer Research UnitedOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT04808362 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours(MYCure) | terminated | Phase 1 / Phase 2 | 22 | Peptomyc S.L.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT03848182 | Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer | terminated | Phase 2 | 10 | Albert Einstein College of MedicineOTHER | 1 | Apr 18, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 23 | Albert Einstein College of MedicineOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04637698 | OH2 Oncolytic Viral Therapy in Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 5 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2023 | clinicaltrials |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 7 | Zhen Wang, MDOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT03649321 | Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 9 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT00625586 | Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 2 | MacroGenicsINDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 34 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03714555 | Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine | terminated | Phase 2 | 1 | HonorHealth Research InstituteOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT03490760 | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | terminated | Phase 2 | 9 | Baptist Health South FloridaOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT03140670 | Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy | terminated | Phase 2 | 46 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05435053 | Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer(CHECKPOINT) | terminated | Phase 2 | 9 | Ismail GögenurOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT04644315 | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors(ALpha-T) | terminated | Phase 2 | 1 | Hoffmann-La RocheINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | terminated | Phase 1 / Phase 2 | 48 | GenmabINDUSTRY | 3 | Aug 1, 2023 | clinicaltrials |
| NCT04212026 | Irreversible Electroporation (IRE) Followed by Nivolumab in Patients With Metastatic Pancreatic Cancer. | terminated | Phase 2 | 8 | University Hospital, Basel, SwitzerlandOTHER | 1 | Jul 18, 2023 | clinicaltrials |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT00227617 | Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors | terminated | Phase 2 / Phase 3 | 36 | University of California, San FranciscoOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03099265 | Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Yale UniversityOTHER | 1 | Oct 27, 2022 | clinicaltrials |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT01461915 | Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients(PGPC1) | terminated | Phase 2 | 60 | Jazz PharmaceuticalsINDUSTRY | 1 | Jun 6, 2022 | clinicaltrials |
| NCT04176952 | PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer(PRIMUS002) | terminated | Phase 2 | 31 | Judith Dixon-HughesOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT04327986 | Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | May 18, 2022 | clinicaltrials |
| NCT04258150 | Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer(TRIPPLE-R) | terminated | Phase 2 | 26 | Herlev HospitalOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03637491 | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 3 | Jan 26, 2022 | clinicaltrials |
| NCT03331640 | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy(PANTHEON) | terminated | Phase 2 | 67 | AIO-Studien-gGmbHOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04070313 | A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan | terminated | Phase 2 | 36 | TTY BiopharmINDUSTRY | 1 | Dec 6, 2021 | clinicaltrials |
| NCT03599362 | Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer | terminated | Phase 2 | 7 | NYU Langone HealthOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT01784861 | VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors | terminated | Phase 1 / Phase 2 | 23 | Washington University School of MedicineOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2021 | clinicaltrials |
| NCT02985801 | PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 16 | Massimo Raimondo, M.D.OTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Medstar Health Research InstituteOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT00066677 | Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer | terminated | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT02921737 | TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003) | terminated | Phase 2 | 7 | University of FloridaOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT03585062 | Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer | terminated | Phase 2 | 40 | Zhejiang Provincial People's HospitalOTHER | 1 | Jan 8, 2021 | clinicaltrials |
| NCT00003531 | Antineoplaston Therapy in Treating Patients With Stage IV Pancreatic Cancer | terminated | Phase 2 | 15 | Burzynski Research InstituteOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT00493441 | AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer | terminated | Phase 2 | 28 | Vertex Pharmaceuticals IncorporatedINDUSTRY | 1 | Sep 30, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 13, 2024source: clinicaltrials